Institutions / Lynx1 Capital Management LP
Lynx1 Capital Management LP
CIK 1910456 · Institution · as of Dec 31, 2025
Portfolio value
$494.00M
Positions
22
As of
Dec 31, 2025
Top holdings
Dec 31, 2025
| Company | Value | % of portfolio |
|---|---|---|
| Stoke Therapeutics, Inc. | $171.54M | 34.7% |
| Gh Research PLC | $132.16M | 26.8% |
| Cullinan Therapeutics, Inc. | $92.77M | 18.8% |
| Denali Therapeutics Inc. | $28.71M | 5.8% |
| C4 Therapeutics, Inc.CCCC | $13.56M | 2.7% |
| Xencor Inc | $10.80M | 2.2% |
| Immatics N.V | $9.68M | 2.0% |
| TScan Therapeutics, Inc.TCRX | $8.02M | 1.6% |
| Passage BIO, Inc.PASG | $7.36M | 1.5% |
| Korro Bio, Inc. | $5.43M | 1.1% |
| Precision BioSciences, Inc. | $4.13M | 0.8% |
| Neuphoria Therapeutics Inc.NEUP | $3.40M | 0.7% |
| Agios Pharmaceuticals, Inc. | $2.17M | 0.4% |
| CG Oncology, Inc. | $1.31M | 0.3% |
| Arrowhead Pharmaceuticals, Inc. | $799.5K | 0.2% |
| Design Therapeutics, Inc.DSGN | $652.1K | 0.1% |
| Entrada Therapeutics, Inc.TRDA | $531.4K | 0.1% |
| Werewolf Therapeutics, Inc.HOWL | $415.5K | 0.1% |
| Maplight Therapeutics IncMPLT | $236.7K | 0.0% |
| Generation Bio Co | $142.0K | 0.0% |
| Proqr Thrapeutics N V | $138.3K | 0.0% |
| Applied Therapeutics Inc | $41.0K | 0.0% |
Activity
Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.